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Background and aims: Binge eating disorder (BED) is a relatively common condition, especially in young adult fe-
males, and is characterized by chronic over-consumption of food resulting in embarrassment, distress, and potential
health problems. It is formally included as a disorder in DSM-5 for the first time, an acknowledgement to its debilitat-
ing nature. This article explores the overlap between binge eating disorder and substance use disorders (SUD). Meth-
ods: The bibliographic search was a computerized screen of PubMed databases from January 1990 to the present.
Binge eating disorder, substance use disorder, binging, obesity, food addiction, comorbidity, dopamine, opioid, sero-
tonin, glutamate, and pharmacological treatment were the keywords used in searching. Results: BED shares similar
phenomenology to SUD, including significant urges to engage in binging episodes, resulting in distress and impair-
ment. Similar neurobiological pathways are found in both BED and SUD and medications based on similar
neurobiology have been examined for both disorders. A subset of individuals with BED may have a “food addiction”,
but there is no clinical agreement on the meaning of “food addiction”. Exploring the relationship between BED and
obesity may also shed light on the extent to which BED can be viewed as an addiction. Conclusions: Overall, nascent
research regarding BED and SUD suggests an overlap between these disorders, but there are discrepancies between
these two disorders that need further exploration.
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INTRODUCTION
Binge eating disorder (BED) is a disorder characterized by
the compulsive engagement in excessive food consumption
which results in feelings of guilt or shame and, in many
cases, physical problems (American Psychiatric Associa-
tion, 2013). Despite the mirroring characteristics, such as in-
creased tolerance to the amount of food or substances con-
sumed, triggering urges to consume food or substances, and
similar dopaminergic and opiate pathways for highly palat-
able foods and substances, between binge eating and sub-
stance addictions, exploring the intersect between these two
is relatively recent. This article provides a brief overview of
the current literature on BED and discusses the overlap of
BED with substance use addictions (e.g., illicit drug, nico-
tine, and alcohol dependence; SUD) in order to better under-
stand the nature of BED.
METHODS
All literature was found through the search engine PubMed
from January 1990 to the present. Keywords for locating ar-
ticles included: binge eating disorder, binging, substance
use disorder, obesity, food addiction, comorbidity, dopa-
mine, opioid, serotonin, glutamate, and pharmacological
treatment. The keywords “binge eating disorder”, “bing-
ing”, and/or “substance use disorder” were used alone in all
searches and were combined with each of the previously
mentioned keywords. Each search resulted in a varying
number of articles with binge eating disorder and glutamate
providing only 5 results, and substance abuse and pharma-
cological treatment resulting in 88,251 articles. Binge eating
disorder and substance use disorder resulted in 151 articles.
Articles reviewed for this publication were based on publi-
cation date, with articles from the year 2000 onwards as the
focus, and the degree to which the article related to both
binge eating disorder and substance use disorders. A total of
70 publications were reviewed for this paper, including 11
articles published between 1990 and 2000 that were addded
due to the additional support they provided.
EPIDEMIOLOGY AND PHENOMENOLOGY
BED occurs in about 1.4% (0.8% to 1.9%) of the global pop-
ulation and has a mean age of onset of approximately 23
years (Kessler et al., 2013). BED occurs more frequently in
young adults (ages 18–29), females, and college-educated
and student populations (Kessler et al., 2013). Interestingly,
males and females may have similar binge episode fre-
quency, but males report less distress compared to females,
and therefore, do not meet full BED criteria (Lewinsohn,
Seeley, Moerk & Striegel-Moore, 2002). Similar to BED,
SUD peaks in late adolescence and young adulthood. Males
with BED, however, are about two times more likely to have
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a SUD compared to females; yet, higher rates of specific ad-
dictions, such as cocaine, psychotherapeutic drugs, and per-
sistent alcohol use disorder have been noted in females
(Merikangas & McClair, 2012). People rarely seek treat-
ment for binge eating or admit to it on direct questioning
(Dingemans, Bruna & van Furth, 2002). The complications
of binge eating – excessive weight and health problems re-
lated to excessive weight (e.g., morbid obesity; diabetes;
pulmonary and cardiac problems) – are the usual reasons
people seek treatment (Dingemans et al., 2002).
BED also negatively impacts quality of life in a variety
of domains, including physical, emotional, social, and per-
sonal well-being (Tanofsky-Kraff et al., 2013). Individuals
with BED may avoid social events, especially in situations
where food is present, because of negative emotionality or
out of fear they will binge in front of others (Smith & Rob-
bins, 2013). Typically, binge eating is secretive, accompa-
nied by a negative mood and cognitive rigidity, and may be
an attempt to cope with negative emotionality (Sim et al.,
2010). Risk factors for BED may include the personality
traits of neuroticism and urgency, impulsivity, a tendency
toward experiencing negative emotionality and a socio-cul-
tural environment that enforces the ability of food to reduce
negative emotionality (Ferriter & Ray, 2011). Individuals
with SUDs also score highly on measures of impulsivity,
sensation seeking, and have high levels of emotional
dysregulation (Grant, Potenza, Weinstein & Gorelick,
2010).
Research has cited high comorbidity rates between BED
and SUD. About one-fourth (24.8%) of individuals with
BED report having a lifetime SUD, while 2.7% have a cur-
rent SUD. Heightened levels of SUDs have also been found
in relatives of those with BED (Lilenfeld, Ringham,
Kalarchian & Marcus, 2008). Greater lifetime and current
SUD comorbidity rates have been cited in males with BED
(40.4% and 5.3%, respectively) compared to females
(20.0% and 1.9%, respectively) (for rates of the co-morbid
disorders, see Grilo, White & Masheb, 2009), suggesting
that gender may factor into the overlap between BED and
SUD.
DIAGNOSIS AND ASSESSMENT
For the first time within DSM history, BED is formally in-
cluded as a disorder in the DSM-5. Previously BED was
classified as a disorder for further study in Appendix B of
the DSM-IV. The following are the diagnostic criteria for
DSM-5 (American Psychiatric Association, 2013) binge
eating disorder; A) Recurrent binge eating episodes which
are experienced as having a loss of control over eating, occur
within a discrete period of time (within 2 hours), and involve
eating a significantly larger amount of food than most peo-
ple would eat in a similar time period; B) Binge eating epi-
sodes that are associated with at least three of the following:
eating rapidly; eating until uncomfortably full; consuming
large quantities of food when not physically hungry; eating
alone due to embarrassment; and/or feeling disgust, de-
pressed, or guilty post-binge; C) Binge eating produces dis-
tress; D) Binge eating episodes occur at least one time per
week for three months; and E) Binge eating is not accompa-
nied by compensatory behavior. Severity of binge eating
disorder is classified as the following: mild – 1 to 3 binge
eating episodes per week; moderate – 4 to 7 binge eating epi-
sodes per week; severe – 8 to 13 binge eating episodes per
week; extreme – 14 or more binge eating episodes per week.
The following are the diagnostic criteria for DSM-5
(American Psychiatric Association, 2013) substance-related
and addictive disorders, which encompass 10 different
classes of drugs. A) Using substances for a greater amount
of time or using a greater quantity of substance than in-
tended; B) Despite intent to decrease substance use, inability
to reduce or regulate substance use; C) A large amount of
time is occupied by obtaining, using, or recovering from the
effects of the substance; D) A craving is experienced to use
the substance; E) Work, school, or home obligations are in-
terfered with due to substance use; F) Consistent social and
interpersonal problems result from substance use; G) With-
draw from social, occupational, or recreational activities due
to substance use; H) Continued use of substances despite the
negative physical and psychological consequences; I) In-
creased substance tolerance over time; J) Experience with-
drawal symptoms when ceasing substance use. Mild severity
substance use is categorized as the presence of 2 to 3 symp-
toms, moderate is 4 to 5 symptoms, and severe is 6 or more
symptoms.
Similarities noted between these diagnostic symptoms
include eating larger amounts of food than intended; inabil-
ity to decrease binge eating, despite concerted efforts;
spending substantial amounts of time binging or recovering
from the effects of binging; reducing other pleasurable ac-
tivities due to binging; and binging despite persistent nega-
tive consequences (Cassin & von Ranson, 2007). Both BED
and SUD are triggered by cravings/urges and affective states
and may serve to regulate negative affect (Gearhardt, White
& Potenza, 2011; Luce, Engler & Crowther, 2007). These
diagnostic and behavioral phenotypic similarities support
the similarities between BED and SUD, but do not necessar-
ily mean that they should be categorized similarly.
When applying SUD diagnostic criteria to BED, several
issues arise. First, the concept of “out of control” differs.
Consuming a greater amount of alcohol than intended de-
scribes the “out of control” nature in SUD, which is some-
what subjective given the use of the word “intended”. In
contrast, the “out of control” in BED refers to consuming an
objectively large amount of food in a discrete time period
(Gearhardt et al., 2011), which is more objective in nature
due to the wording “discrete time period”. Furthermore, a
large amount of food eaten throughout the day may not be
diagnostically considered “out of control”, whereas con-
suming a large amount of alcohol throughout the day may be
considered “out of control”.
SUD criteria also differentiate between 10 different sub-
stances, whereas BED diagnostic criteria do not specify the
addictive component of food (American Psychiatric Associ-
ation, 2013; Gearhardt et al., 2011). Differentiating between
substance types is useful, since addictive substances have a
different specific effect on the brain (i.e., opiates target
opioid receptors). Since food is a mixture of macro- and
micronutrients, food has a widespread impact on the body
and impacts multiple brain receptors (see Volkow, Wang,
Tomasi & Baler, 2013 for a review on how food differen-
tially impacts the body). Potential candidates for addictive
substances include sugar and other refined sweeteners, fat,
refined carbohydrates, and salt (Ifland et al., 2009). The
mechanisms of how each nutrient in food influence the
neurobiological pathways of reward and motivation systems
are not well understood due to the complex nature of metab-
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olism. However, through animal models, researchers are be-
ginning to understand how sugar and fat impacts various
neurological pathways (see the Neurobiological underpin-
nings section below). Additionally in BED, food-seeking
motivation and behaviors may come from individual factors,
such as eating related cognitive distortions, body weight
concerns, and dietary restriction, as well as excessive con-
sumption of highly processed food (Gearhardt et al., 2011).
FOOD ADDICTION AND BINGE EATING
Currently, clinicians and researchers are discussing the va-
lidity of characterizing BED as a food addiction (FA). Pro-
ponents of food addiction describe the similar neuro-
biological underpinnings of BED and SUDs (see the Neuro-
biological underpinnings section below for more details)
and highlight the similar experiences between the two popu-
lations, such as an out of control feeling, urges, and trigger-
ing emotional states (Gearhardt et al., 2011).
The development of the Yale Food Addiction Scale
(YFAS; Gearhardt, Corbin & Brownell, 2009) highlights the
similarities between food addiction and overeating. The
YFAS modified the DSM-IV substance dependence criteria
for food (see Gearhardt et al., 2009 for these criteria) and
classifies individuals as having FA by meeting three or more
diagnostic criteria and at least one of two clinically signifi-
cant items (for a more detailed review see Ziauddeen &
Fletcher, 2012).
Using the YFAS scale, 56.8%–72% of individuals who
met FA criteria, also met criteria for BED; while only 24%
who did not meet FA criteria, met diagnostic threshold for
BED (Davis et al., 2011; Gearhardt et al., 2011). Participants
meeting both FA and BED criteria were found to have a
greater propensity towards impulsivity and hedonic eating
(Davis et al., 2011). Using the DSM-IV substance abuse cri-
teria modified for binge eating, however, Cassin and von
Ranson (2007), who found that a majority (92.4%) of indi-
viduals with BED met diagnostic standards for “food addic-
tion”. While these results highlight similarities between FA
and BED, they also suggest the possibility that FA exists in a
subset of individuals with BED (possibly in the highly im-
pulsive individuals with BED) and the need for well-estab-
lished definition and criteria for FA in order to progress re-
search.
NEUROBIOLOGICAL UNDERPINNINGS
OF BED AND SUD
Understanding the neurobiology underlying BED may help
clinicians better understand the nature of the disease, as well
as how to best classify this disorder. Both BED and SUD
have been associated with reduced activity in the orbito-
frontal and prefrontal cortex areas, which are associated
with self-control, as well as dysfunctional dopamineric and
opioid pathways (Smith & Robbins, 2013). Polymorphisms
on the OPRMI mu-opioid receptor gene (A118G) and
DRD2 dopamine receptor gene (Taq1A A1) have been
found in both samples of BED and SUDs, and may increase
their vulnerability to the reward characteristics of food and
substances (Davis et al., 2009; Wang, Volkow, Thanos &
Fowler, 2004).
Dopamine and opiate hypotheses
Dopaminergic and opioid pathways both play an important
role in feeding behavior and the maintenance of a SUD. Do-
pamine is involved in the motivation to participate in re-
warding activities, as well as influencing conditioned rein-
forcement and prepotent conditioning in the mesolimbic do-
pamine system; opiates are involved in the enjoyment of the
rewarding activity (Davis et al., 2009; Wise, 2004). These
neurotransmitter pathways, however, do not function inde-
pendently, but are rather intertwined. Dopaminergic signals
can be altered by other neurotransmitters, such as endoge-
nous opioids, and some opiate signal pathways need a func-
tional dopamine D2 receptor to function (Davis et al., 2009).
Researchers have used animal models to better under-
stand the role of dopaminergic and opioid pathways in the
complex relationship between feeding and addictions. For
example, sucrose-dependent rodents display delayed satia-
tion, consume more sucrose, and release more dopamine in
the accumbens shell (Davis & Carter, 2009) as well as
blunted activity in the cortical-striatal regions (Hommer
et al., 2012). Similarly, both drugs of abuse and highly palat-
able food (high in sugar and fat) can increase dopamine lev-
els, enhancing the stimulus-reward association (Davis &
Carter, 2009; Koob & Le Moal, 2001). Studies have found
that both overfeeding and extended access to intravenous
cocaine or heroin self-administration were related to the dis-
ruption of reward processing and diminished reward (John-
son & Kenny, 2010). Additionally, subsequent to 12 hours
of intermittent food deprivation, rodents consume a high su-
crose solution in a binge-like manner and ingest the majority
of their daily caloric intake within the first hour of access,
which parallels drug consumption behaviors of drug-de-
pendent individuals (Avena, Rada & Hoebel, 2008). Fur-
thermore, decreased consumption of and preference for,
high fat/high sugar foods have been found after the adminis-
tration of opioid receptor antagonists (Cottone, Sabino,
Steardo & Zorrilla, 2008), while an increased preferential
intake of high-fat/high sugar items after injections of opioid
agonists in the striatum was found in satiated rodents
(Zhang, Gosnell & Kelley, 1998). Overall, these studies sug-
gest that both the consumption of food and drugs may be an
attempt to alleviate the reduced reward (Johnson & Kenny,
2010) and that individuals may use drugs of abuse and
highly palatable food as a means of self-medicating a
hypoactive dopaminergic system.
Similar somatic withdrawal symptoms have been found
in rodents who were raised in a sucrose binge model after re-
moving sucrose access and after administering an opioid an-
tagonist (naloxone) and after food is removed for 24 hours
(Avena, Rada & Hoebel, 2009). Neurochemically, similar
alterations in dopamine and opioids are found in withdrawal
from sucrose binges and from morphine, nicotine, and alco-
hol (Avena et al., 2009). Fat binging, however, has not been
found to result in the opiate-like withdrawal symptoms as
seen with sucrose. The differential impact of fat binging
could be a result of the activation of the inhibitory
neuropeptide galanin-induced by fat binging, which may in-
hibit the opiate-like withdraw response (Avena et al., 2009).
Thus in moving forward in examining the overlap between
BED and SUD, differentiating between how the different
types of macronutrients (i.e. sugar and fat) impact reward
pathways and receptor types may be beneficial.
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For example, research into the specific receptor subtypes
(mu, delta, and kappa) of the opioid receptor system has par-
ticularly implicated the mu-opioid receptor, which is in-
volved in appetite regulation and hedonic processing of food
related stimuli (Chamberlain et al., 2012) in BED. Specifi-
cally, the antagonism of this receptor has led to short-term
reductions in palatable/high calorific food (in individuals
with binge eating) and clinical alcohol use, as well as
attentional bias for food cues (Chamberlain et al., 2012). A
further examination of the different opioid receptors may aid
in understanding of the crossover between binge eating and
addiction.
Pharmacotherapies targeting the mu opioid receptor
have illustrated the potential benefits of opiate antagonists in
the treatment of BED, in that studies have found that opiate
antagonists decrease food intake and food seeking behavior
in human and animal models (Cambridge et al., 2013). Gar-
butt, West, Carey, Lohr and Crews (1999) hypothesized that
naltrexone may work through decreasing the emotional re-
sponse to alcohol consumption; thus it is possible that
naltrexone may also alter one’s subjective emotional re-
sponse (i.e., decrease the pleasantness of palatable food) to
food, which may lead to decreased binge episodes (Rabiner
et al., 2011). Only one randomized, placebo-controlled trial
included individuals with BED, which found decreased
binge duration and frequency in obese binge eaters taking
naltrexone (at dosages of 100–150 mg/d); however, the
naltrexone group was not significantly differentiated from
compared to placebo (Alger, Schwalberg, Bigaouette,
Michalek & Howard, 1991). Yet, three case reports found
naltrexone were useful in treating BED using higher dosages
of 200 to 400 mg/day (Marrazzi, Markhan, Kinzie & Luby,
1995) and augmentation with fluoxetine (Meyer, 2008;
Neumeister, Winkler & Wober-Bingol, 1999). A similar
medication, naloxone, which is an opiate blocker and is pro-
posed to decrease reward response, has been useful, how-
ever, in decreasing intake of high sugar and high fat food in
both lean and obese binge eaters (Drewnowski, Krahn,
Demitrack, Nairn & Gosnell, 1995).
One of the most widely studied pharmacotherapeutic in-
tervention for SUDs are opioid antagonists (such as
naltrexone) and partial agonists (such as nalmefene) which
have been found to be effective in the treatment of patients
with alcohol and nicotine dependence. Double-blind, ran-
domized, controlled trials have found that compared to pla-
cebo, naltrexone may help reduce number of days drinking,
amount of alcohol consumed, number of relapses (Snyder &
Bowers, 2008), and especially in those who complete treat-
ment. King, Cao, Zhang and O’Malley (2013) recently
found that nicotine-dependent females treated with
naltrexone had significantly less weight gain at a one-year
follow-up after achieving abstinence from nicotine, suggest-
ing that opioid antagonist treatment may decrease urges
prompting binge eating episodes after cessation from sub-
stance addiction.
Minimal research has explored dopamine in the treat-
ment of BED. Past research found bupropion, a selective
reuptake inhibitor of dopamine and norepinephrine, effec-
tive for decreasing nicotine and food related cravings
(Brody et al., 2004; Jain et al., 2002; Jorenby et al., 1999).
Only one randomized, controlled trial has examined bupro-
pion in BED, finding that the active medication did result in
short-term weight loss compared placebo, but was not asso-
ciated with decreases in binge eating or food cravings
(White & Grilo, 2013). In a double-blind study of sus-
tained-released bupropion for smoking cessation in a large
sample, researchers found that bupropion was superior to
placebo in decreasing smoking (Sheng et al., 2013).
Overall, a fair amount of research has investigated the
role of the dopaminergic and opioid pathways in the motiva-
tion and reward of food and drug related behaviors through
animal models; however, pharmacological human trials
modifying these neurotransmitters are relatively novel for
BED and need further investigation. Based on research pre-
sented above, targeting the opioid pathways show promise
and future studies may want to further explore the use of
opioid antagonists that alter the mu-opioid receptor in treat-
ing BED.
Serotonin – Acute tryptophan depletion (ATD) hypothesis
Low levels of tryptophan have consistently been shown to
result in carbohydrate/fat rich, highly palatable food binges
(Corsica & Spring, 2008). Tryptophan, the most scarce
amino acid, is essential for serotonin synthesis and is greatly
increased after consuming a meal high in carbohydrates
(through the action of insulin; Fortuna, 2012; Schaechter &
Wurtman, 1990). Theories suggest that low baseline seroto-
nin levels decrease inhibitory control over food and drug
cravings and heighten the desire for sweet foods, opposing
impulse regulation when exposed to rewarding (i.e., highly
palatable) foods (Fortuna, 2012). Using animal models,
Asin, Davis and Bednarz (1992) found decreased sucrose in-
take with the administration of increasing dosages of seroto-
nin agonists. Greater serotonin levels (as a result of D-fen-
fluramine) were also associated with the reduction of smok-
ing withdrawal symptoms (such as increased carbohydrate
intake and weight gain) in overweight females (Spring,
Wurtman, Gleason & Kessler, 1991). Heightened alcohol
cravings have been associated with lower levels of serotonin
availability at synapses and with acute tryptophan depletion
(Ait-Daoud et al., 2009).
Overall, selective serotonin reuptake inhibitors (SSRIs)
have been found to decrease binge eating and weight symp-
toms, as well as improved mental health in individuals with
BED in eight randomized, placebo-controlled trials that
lasted between 6 and 20 weeks (McElroy, Guerdjikova,
Mori & O’Melia, 2012). Researchers have found that in
samples of individuals with DSM-IV BED, fluvoxamine
and sertraline were related to significantly reduced binge
frequency and BMI, as well as decreased severity of BED
compared to placebo (Hudson et al., 1998; McElroy et al.,
2000). Contrarily, little evidence, however, supports the use
of SSRIs in treating individuals with alcoholism, with three
of four randomized controlled monotherapy trials not show-
ing any significant differences between active medication
and placebo (Miller, Book & Stewart, 2011). SSRIs are also
not recommended for either first or second-line treatments
for nicotine, opioid, cocaine, or cannabis dependence (van
den Brink, 2012). Since SSRIs may benefit some with BED,
while not much evidence supports treating SUDs with
SSRIs, this suggests that differing neurobiological mecha-
nisms are dysfunctional in BED versus SUD and that BED
may have more overlap with mood disorders than SUD does
with mood disorders.
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Glutamate hypothesis
Glutamate has been found to play a role in the regulation of
food intake, drug seeking behavior, and modifying binge
eating (McElroy et al., 2011; Tata & Kockler, 2006). More
specifically, increased food intake has been associated with
the blockage of glutamate receptors within the nucleus
accumbens (Maldonado-Irizarry, Swanson & Kelley, 1995).
In animal models, restoring glutamate activity to normal lev-
els, decreases cocaine- and heroin-seeking and slows recon-
ditioning to alcohol and cocaine (Baker et al., 2003; Myers,
Carlezon & Davis, 2011). Both acamprosate (a glutamate
N-methyl-D-aspartate receptor antagonist) and topiramate
(a glutamate kainate receptor antagonist) have been ex-
plored as treatment options for both BED and SUDs.
Acamprosate, which is a glutamate N-methyl-D-aspar-
tate receptor antagonist, may reduce mGluR5 function, and
is approved for alcohol dependence (Miller et al., 2011),
has been found to decrease food craving and weight gain in
individuals with alcoholism (McElroy et al., 2011, 2012).
Acamprosate has been used in one randomized, placebo-
controlled trial for BED, and fourteen trials have compared
acamprosate to placebo in individuals with alcoholism.
For the one BED trial with acamprosate, McElroy et al.
(2011) found that although acamprosate was not associated
with significantly decreased binge frequency, it was associ-
ated with secondary measures of binge day frequency, food
craving, and obsessive–compulsive symptoms of binge eat-
ing. BMI was also significantly decreased in participants re-
ceiving the active medication compared to placebo
(McElroy et al., 2011) suggesting acamprosate may benefit
some individuals with BED. Even though acamprosate has
been approved for alcohol dependence, overall, randomized,
placebo-controlled trials have only provided mixed evi-
dence regarding efficacy, with seven studies favoring
acamprosate and seven providing mixed results or no signif-
icant differences when compared to placebo (Miller et al.,
2011).
Topiramate is an antiepileptic drug found to be useful for
alcohol dependence, weight-loss, and BED (Claudino et al.,
2007; McElroy et al., 2003, 2007) and has been examined in
three randomized, placebo-controlled trials. Two of the
three trials found that compared to the placebo-group, those
receiving topiramate had significant reductions in binging
frequency (Claudino et al., 2007; McElroy et al., 2007).
Even though one trial found that topiramate did not decrease
binging frequency, all three trials found that the topiramate
group had greater weight loss and a higher remission rate of
binge eating compared to placebo (Claudino et al., 2007;
McElroy et al., 2003, 2007).
As previously mentioned, topiramate has demonstrated
promising efficacy for alcohol dependence as well. In a ran-
domized, double-blind study of 150 individuals with alcohol
dependence, researchers found that topiramate treatment re-
sulted in significant improvements in all drinking measures,
as well as an objective biochemical measure of alcohol,
compared to placebo (McElroy et al., 2003). Further, a
meta-analysis of 3 placebo-controlled trials of topiramate
and alcohol dependence found that topiramate groups had
significant improvement in subjective and objective mea-
sures of alcohol dependence, such as significantly lower
rates of g-GT and significantly more days of alcohol absti-
nence and fewer days of high alcohol consumption
(Arbaizar, Dierssen-Sotos, Gómez-Acebo & Llorca, 2010).
Targeting the glutamatergic system with treatment may
provide a promising treatment for some individuals with
BED, especially in those who are obese. Moving forward,
researchers may want to further investigate glutamate based
treatment, such as topiramate and acamprosate, for BED.
NEUROBIOLOGICAL UNDERPINNINGS
OF BED AND OBESITY
Approximately 36% of binge eaters have been obese in their
lifetime (Gadalla & Piran, 2007), while between 23%–46%
of obese individuals report BED (Bulik, Sullivan & Kendler,
2002), indicating that obesity and BED are not synonymous.
Examining the neurobiological similarities and differences
between BED and obesity may help researchers understand
how BED diverges from SUDs. Similar to SUDs, recent re-
search using functional magnetic resonance imaging sug-
gests a subgroup of obese individuals with binge eating dis-
order exists that have hypoactivity in the ventromedial
prefrontal cortex, inferior frontal gyrus, and insula; areas of
the brain highly implicated in reward and motivational be-
haviors and associated with impulse control (Balodis et al.,
2013).
Dopamine
As previously mentioned BED has been associated with al-
tered dopaminergic functioning. Dysfunctional dopamine
may also be associated with obesity. In animal models, one
study found that rats (both obesity-prone and obesity-resis-
tant rats) increased their intake of high fat food, while,
decreasing their intake of “regular” food after receiving
bromocriptine (a dopamine, DRD2, agonist). At a dosage of
20 mg/kg, both obesity-resistant and obesity-prone rats
pressed the food level during the non-reinforcement period
at significantly greater rates compared to their baseline;
whereas only obesity-prone rats increased these lever
presses at bromocriptine dosages of 10 mg/kg of body
weight. These results underscore dopamine’s role (specifi-
cally the D2 receptor) in increased motivational drive for
highly palatable food and suggest that treatments targeting
DRD2 activity may be useful for impulsive, obesity-prone
individuals (Thanos, Bermeo, Wang & Volkow, 2011).
In human trials, some studies have found a negative as-
sociation between BMI and striatal D2R binding and a posi-
tive correlation between striatal D2R binding and prefrontal
metabolism, suggesting that both a dysfunction in the re-
ward pathway and reduced inhibitory control may contrib-
ute to obesity (Volkow et al., 2008; Wang et al., 2001).
However, the negative association between BMI and striatal
dopamine binding were not replicated in a more recent study
when comparing overweight or obese individuals to normal
weighted controls (Haltia et al., 2007). One possible expla-
nation for these differences could be that there was a large
difference between sample BMIs, with the initial study hav-
ing a mean BMI of 51.2 and in the more recent study, over-
weight males and females had a mean BMI of 31.8 and 34.4,
respectively. Yet in 2011, Wang et al. found that baseline
levels of the dopamine D2 receptor availability in the
striatum did not differ between binge and non-binge eaters
and had no correlation with BMI. Thus, studies comparing
individuals with and without BED provide heterogeneous
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neurobiological results in regards to dopamine and cannot
specifically be applied to the distinctiveness of BED. See
Ziauddeen, Farooqi and Fletcher (2012) for a comprehen-
sive review of this data.
Treatments targeting dopamine in treating obesity are
also relatively recent and few trials have been completed.
Bupropion, a selective reuptake inhibitor of dopamine and
norepinephrine, has been found effective (at dosages of
300 mg/d and above) in placebo-controlled trials which in-
volved overweight and obese subjects taking the bupropion,
coupled with a 400 to 600 daily calorie deficit, reporting sig-
nificant weight loss when compared to placebo (Anderson
et al., 2002; Gadde et al., 2001; Jain et al., 2002). The combi-
nation of bupriopion and naltrexone has also been found to
significantly decrease weight over a 48-week period in a
sample of obese patients (Greenway et al., 2009).
Based on findings from animal models and as well as hu-
man studies, dysfunctional dopamine pathways most likely
play a role in the development of obesity and BED. Target-
ing dopamine receptors when treating BED may be useful,
however, further research needs to be completed to better
understand the nature of the specific dopaminergic receptors
that influence the development of BED.
CONCLUSIONS
A level of overlap exists in the phenomenology, clinical
characteristics, and treatment efficacy between substance
dependence and binge eating disorder. Research into animal
models has illustrated that dopaminergic and opioid path-
ways play similar roles in the hedonic and rewarding proper-
ties of drugs and food and that serotonin and glutamate may
also be important in the regulation of food intake and sub-
stance use. With such a limited caché of in vivo or in vitro re-
search exploring the pathophysiology of BED, however,
conclusions as to the extent of the overlap between BED and
SUD and the appropriateness of labeling BED (or a sub-
group of individuals within BED) as a “food addiction” re-
main unknown.
A number of the diagnostic characteristics seen in BED
overlap with SUD, including binging in larger than intended
amounts, continuing to binge despite negative conse-
quences, and reducing other pleasurable activities due to
binging. The hedonistic quality to binging followed by
shame or remorse may suggest similar neurobiological un-
derpinnings to addiction in individuals with BED. Further,
understanding whether age, gender, racial or ethnic back-
ground have an impact on the development of illness is im-
portant and largely lacking from the nascent BED literature.
In regard to BED and addiction, further examining family
history, comorbidity, and clinical characteristics between
and within these disorders will aid in triaging patients for
proper care, lessening the mental and physical health burden
associated with prolonged binge eating and addiction.
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